当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Katsuhiro Toda
A 58-year-old male (162.1 cm, 76.8 kg, body mass index 29.2) suffered from intermittent claudication. At the initial visit, walking 10-100 meters caused pain in lateral part of the right lower limb, resulting in inability to walk. Xray showed mild forward slip of the fifth lumbar vertebra, however, MRI did not show narrowing of the lumbar canal. He could walk at least 1 km without pausing with Neurotropin®. If he failed to take Neurotropin®, he suffered from pain of the right lower limb. Four months later, he weighed 71.0 kg. He discontinued Neurotropin®, however, he did not feel pain during walking.
In the patient, weight reduction eliminated intermittent claudication without effective medicine. It is unclear whether the patient suffered from lumbar canal stenosis (LCS). Weight reduction is one of the first-line treatments in obese or overweight patients with LCS. Weight reduction is a safe and inexpensive treatment. Even if weight reduction does not alleviate symptoms, it improves overall health in former obese or overweight persons. However, we should not recommend weight reduction to patients whose first priority is maintaining of the amount of food.